期刊
CURRENT PHARMACEUTICAL DESIGN
卷 9, 期 12, 页码 997-1004出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612033455116
关键词
neuropeptides; vasoactive intestinal peptide; pituitary adenylate cyclase activating polypeptide; Th1/Th2 effector cells; macrophages
资金
- NIAID NIH HHS [AI 41786, AI 47325] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI041786, R01AI041786, R01AI047325, R56AI047325, R01AI147325] Funding Source: NIH RePORTER
The structurally related neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) are released within the lymphoid organs following antigenic stimulation, and modulate the function of inflammatory cells through specific receptors. In activated macrophages, VIP and PACAP inhibit the expression at both mRNA and protein level of pro-inflammatory cytokines and chemokines, through effects on tic novo expression or nuclear translocation of a number of transcription factors, i.e, NFkB, CREB,C-Jun, IunB, and IRF-1. In addition, VIP and PACAP promote Th2-type, and inhibit Th1-type responses in vivo and in vitro, through several mechanisms, including preferential survival of Th2 effectors and subsequent generation of Th2 memory cells. The function of VIP/PACAP as macrophage deactivating factors appears to be responsible For their protective effect in vivo in models of septic shock. Both deactivation of macrophagcs and inhibition of Th1-type responses appear to be responsible for the beneficial effect of VIP/PACAP in models of Th1-type autoimmune diseases such as rheumatoid arthritis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据